GSK (NYSE:GSK) Shares Gap Down - Should You Sell?

Key Points

• Shares gapped down — GSK opened at $50.00 after closing at $54.47 and was trading down about 5.3%, a move driven largely by management’s FY2026 revenue guide (~$44.8B) coming in slightly below consensus (~$45.2B) despite an earnings beat.
• GSK beat Q1 EPS ($1.24 vs. $1.16 consensus) and said stronger sales in respiratory and specialty/general medicines lifted core operating profit, while reaffirming full‑year guidance for mid‑to‑high single‑digit core operating profit and EPS growth.
• GSK raised its quarterly dividend (annualized $1.94, ~3.8% yield) even as analysts’ consensus on MarketBeat is a "Reduce" with a $53 target and the stock trades at a P/E of about 13.9.

GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report)'s share price gapped down prior to trading on Wednesday . The stock had previously closed at $54.47, but opened at $50.00. GSK shares last traded at $50.8810, with a volume of 2,390,431 shares.

Key GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Q1 earnings beat — GSK reported quarterly EPS above expectations (reported $1.24 vs. $1.16 consensus), delivering an earnings surprise that signals underlying margin strength. Zacks: GSK Tops Q1
• Positive Sentiment: Profit drivers — Management and reports point to stronger sales in respiratory and specialty/general medicines that lifted core operating profit in Q1, supporting operating leverage. Reuters: GSK beats quarterly profit estimates
• Positive Sentiment: Company reaffirmed FY2026 outlook — GSK reiterated full-year guidance and expects core operating profit and EPS to grow mid-to-high single digits at constant exchange rates, suggesting management confidence in the year. Proactive Investors: GSK reaffirms 2026 guidance
• Positive Sentiment: Options flow showed heavy call buying — Unusually large call volume indicates some traders are positioned for upside into or after the print, which can signal short-term bullish conviction.
• Neutral Sentiment: Revenue/mix was mixed — Reported quarterly revenue was roughly flat year-over-year (modest growth) and the company’s slides/notes show growth concentrated in Specialty while Vaccines and General Medicines were stable to slightly down; this is not uniformly bullish or bearish. MarketBeat: Earnings details & call
• Negative Sentiment: Revenue guidance below Street — Management’s FY2026 revenue guide (~$44.8B) is slightly below consensus (~$45.2B), which helps explain investor caution despite the EPS beat (EPS guide was modestly above consensus). This top-line miss is likely the biggest near-term drag on the stock.
• Negative Sentiment: Policy risk — Broad U.S. policy initiatives (e.g., MFN-related pricing implications) remain a headwind for European pharma pricing and could pressure future U.S. revenues or margins. CNBC: Pharma MFN policy risks

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on GSK shares. Wall Street Zen downgraded shares of GSK from a "strong-buy" rating to a "buy" rating in a report on Saturday, March 7th. Barclays reaffirmed an "underweight" rating on shares of GSK in a report on Friday, February 20th. Morgan Stanley reaffirmed an "underweight" rating on shares of GSK in a report on Wednesday, January 14th. Weiss Ratings lowered shares of GSK from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, March 19th. Finally, TD Cowen reissued a "hold" rating on shares of GSK in a report on Monday, February 9th. One analyst has rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, GSK presently has an average rating of "Reduce" and a consensus target price of $53.00.

GSK Trading Down 5.3%

The stock has a market capitalization of $104.65 billion, a P/E ratio of 13.92, a P/E/G ratio of 3.19 and a beta of 0.46. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.92. The stock's 50 day moving average price is $56.15 and its 200-day moving average price is $51.61.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 9th. Investors of record on Friday, February 20th were paid a $0.4856 dividend. This represents a $1.94 dividend on an annualized basis and a yield of 3.8%. This is a positive change from GSK's previous quarterly dividend of $0.42. The ex-dividend date of this dividend was Friday, February 20th. GSK's payout ratio is presently 50.81%.

Hedge Funds Weigh In On GSK

A number of large investors have recently bought and sold shares of GSK. First Horizon Corp raised its stake in shares of GSK by 78.7% during the 4th quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company's stock worth $26,000 after acquiring an additional 236 shares in the last quarter. Elyxium Wealth LLC bought a new position in shares of GSK during the 4th quarter worth approximately $30,000. CNB Bank bought a new position in shares of GSK during the 3rd quarter worth approximately $31,000. Triumph Capital Management bought a new position in shares of GSK during the 3rd quarter worth approximately $40,000. Finally, Salomon & Ludwin LLC raised its stake in shares of GSK by 444.0% during the 3rd quarter. Salomon & Ludwin LLC now owns 952 shares of the pharmaceutical company's stock worth $41,000 after acquiring an additional 777 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK's core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.